Published in Z Rheumatol on April 01, 2004
[History of the German Society of Rheumatology 1947-2007]. Z Rheumatol (2011) 0.75
Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med (2012) 6.93
Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med (2009) 6.72
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med (2009) 6.61
Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2005) 4.21
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum (2011) 3.60
A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis (2012) 2.40
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis (2006) 2.35
Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis (2010) 1.71
Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum (2011) 1.60
Nonsystemic vasculitic neuropathy: a clinicopathological study of 22 cases. J Rheumatol (2006) 1.39
Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum (2005) 1.36
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis (2011) 1.33
New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. Hum Genet (2004) 1.29
Cartilage destruction in granulomatosis with polyangiitis (Wegener's granulomatosis) is mediated by human fibroblasts after transplantation into immunodeficient mice. Am J Pathol (2012) 1.29
The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum (2005) 1.27
Neurological involvement in Wegener's granulomatosis. Curr Opin Rheumatol (2011) 1.25
Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. Rheumatology (Oxford) (2003) 1.25
Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis (2011) 1.24
Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum (2003) 1.24
Effect of Wegener's granulomatosis on work disability, need for medical care, and quality of life in patients younger than 40 years at diagnosis. Arthritis Rheum (2002) 1.20
Clinical manifestations and treatment of Wegener's granulomatosis. Rheum Dis Clin North Am (2010) 1.18
Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol (2006) 1.17
The SEM6A6 locus is not associated with granulomatosis with polyangiitis or other forms of antineutrophil cytoplasmic antibody-associated vasculitides in Europeans: comment on the article by Xie et al. Arthritis Rheumatol (2014) 1.09
Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther (2011) 1.09
Wegener's granuloma harbors B lymphocytes with specificities against a proinflammatory transmembrane protein and a tetraspanin. J Autoimmun (2010) 1.08
High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum (2002) 1.07
High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther (2009) 1.05
Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol (2012) 1.04
Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum (2002) 1.04
Wegener's granulomatosis. Herz (2004) 1.02
Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res (2001) 1.02
Expansion of circulating NKG2D+ effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener's granulomatosis. Clin Immunol (2008) 1.01
Treatment of ANCA-associated vasculitides (AAV). Autoimmun Rev (2012) 1.00
Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis. Curr Opin Rheumatol (2010) 1.00
Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence? Arthritis Res Ther (2009) 0.99
Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum (2007) 0.99
Progranulin antibodies in autoimmune diseases. J Autoimmun (2012) 0.98
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. J Am Soc Nephrol (2011) 0.98
Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway. Blood (2006) 0.97
Diagnostic significance of ANCA in vasculitis. Nat Clin Pract Rheumatol (2006) 0.96
Vasculitis in 2011: the renaissance of granulomatous inflammation in AAV. Nat Rev Rheumatol (2012) 0.96
CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum (2010) 0.95
Plasma cells within granulomatous inflammation display signs pointing to autoreactivity and destruction in granulomatosis with polyangiitis. Arthritis Res Ther (2014) 0.95
The low-penetrance R92Q mutation of the tumour necrosis factor superfamily 1A gene is neither a major risk factor for Wegener's granulomatosis nor multiple sclerosis. Ann Rheum Dis (2007) 0.94
Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma. Ann Rheum Dis (2010) 0.92
Update on clinical, pathophysiological and therapeutic aspects in ANCA-associated vasculitides. Curr Drug Discov Technol (2009) 0.90
Increased frequency of CCR4+ and CCR6+ memory T-cells including CCR7+CD45RAmed very early memory cells in granulomatosis with polyangiitis (Wegener's). Arthritis Res Ther (2012) 0.90
Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis Rheum (2005) 0.90
Advances in the therapy of Wegener's granulomatosis. Curr Opin Rheumatol (2006) 0.90
Nasal carriage of Staphylococcus aureus and endonasal activity in Wegener s granulomatosis as compared to rheumatoid arthritis and chronic Rhinosinusitis with nasal polyps. Clin Exp Rheumatol (2010) 0.89
Diagnosis and prognosis of early rheumatoid arthritis, with special emphasis on laboratory analysis. Clin Chem Lab Med (2006) 0.89
A functionally relevant IRF5 haplotype is associated with reduced risk to Wegener's granulomatosis. J Mol Med (Berl) (2010) 0.88
On the Wegener granulomatosis associated region on chromosome 6p21.3. BMC Med Genet (2006) 0.88
Lower numbers of FoxP3 and CCR4 co-expressing cells in an elevated subpopulation of CD4+CD25high regulatory T cells from Wegener's granulomatosis. Clin Exp Rheumatol (2010) 0.88
Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology (2002) 0.87
Alterations in the phenotype of CMV-specific and total CD8+ T-cell populations in Wegener's granulomatosis. Cell Immunol (2003) 0.87
20 years with ANCA (antineutrophil cytoplasmic autoantibodies): from seromarker to a major pathogenic player in vasculitis. J Leukoc Biol (2003) 0.87
Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome. J Allergy Clin Immunol (2010) 0.87
Differences in CCR5 expression on peripheral blood CD4+CD28- T-cells and in granulomatous lesions between localized and generalized Wegener's granulomatosis. Clin Immunol (2003) 0.86
Wegener's granulomatosis: the current view. Clin Rev Allergy Immunol (2008) 0.86
A brief history of Wegener's granulomatosis: on limited, localized, and generalized forms of the disease: comment on the article by the Wegener's Granulomatosis Etanercept Trial Research Group. Arthritis Rheum (2004) 0.84
Distinct proteinase 3-induced cytokine patterns in Wegener´s granulomatosis, Churg-Strauss syndrome, and healthy controls. Clin Exp Rheumatol (2011) 0.84
BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of E. coli DH5alpha in vitro. Pediatr Pulmonol (2004) 0.84
Doubled prevalence rates of ANCA-associated vasculitides and giant cell arteritis between 1994 and 2006 in northern Germany. Rheumatology (Oxford) (2014) 0.84
Stable incidence of systemic vasculitides in schleswig-holstein, Germany. Dtsch Arztebl Int (2008) 0.84
Toll-like receptor TLR2 and TLR9 ligation triggers neutrophil activation in granulomatosis with polyangiitis. Rheumatology (Oxford) (2013) 0.83
Comparative analysis of different commercial ELISA systems for the detection of anti-neutrophil cytoplasm antibodies in ANCA-associated vasculitides. Clin Exp Rheumatol (2012) 0.83
Conditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitides. Arthritis Res Ther (2011) 0.83
The role of proteinase 3 (PR3) and the protease-activated receptor-2 (PAR-2) pathway in dendritic cell (DC) maturation of human-DC-like monocytes and murine DC. Clin Exp Rheumatol (2010) 0.83
Development of a CENP-A/CENP-B-specific immune response in a patient with systemic sclerosis. Arthritis Rheum (2002) 0.82
Current state of biologicals in the management of systemic vasculitis. Ann N Y Acad Sci (2007) 0.81
Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother (2004) 0.81
Current understanding of the pathogenesis of granulomatosis with polyangiitis (Wegener's). Expert Rev Clin Immunol (2013) 0.81
Vitronectin- and fibronectin-containing immune complexes in primary systemic vasculitis. J Autoimmun (2002) 0.81
Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage. Rheumatology (Oxford) (2013) 0.81
[Rheumatology -- Part 3. Research news concerning epidemiology, diagnosis, and therapy of primary systemic vasculitides]. Med Klin (Munich) (2006) 0.81
The Schnitzler syndrome: chronic urticaria and monoclonal gammopathy--an autoinflammatory syndrome? J Dtsch Dermatol Ges (2008) 0.81
Frequency of proteinase 3 (PR3)-specific autoreactive T cells determined by cytokine flow cytometry in Wegener's granulomatosis. J Autoimmun (2004) 0.80
Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients. J Rheumatol (2015) 0.80
Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study. Clin Exp Rheumatol (2010) 0.79
Heterogeneity of CD4 and CD8+ memory T cells in localized and generalized Wegener's granulomatosis. Arthritis Res Ther (2002) 0.79
Diagnostic and therapeutic management of Churg-Strauss syndrome. Expert Rev Clin Immunol (2009) 0.79
Contrasting association of a non-synonymous leptin receptor gene polymorphism with Wegener's granulomatosis and Churg-Strauss syndrome. Rheumatology (Oxford) (2010) 0.79
Association of an NKG2D gene variant with systemic lupus erythematosus in two populations. Hum Immunol (2010) 0.79
Genetic association studies in ANCA-associated vasculitides: what we have learnt so far and what needs to be done in the future. Clin Exp Rheumatol (2010) 0.79
Methotrexate plus leflunomide for the treatment of relapsingWegener's granulomatosis. A retrospective uncontrolled study. Clin Exp Rheumatol (2010) 0.78
Treatment of refractory giant cell arteritis with cyclophosphamide:a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol (2012) 0.78
Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein. Inflamm Bowel Dis (2004) 0.78
Membrane proteinase 3 (mPR3) expression on neutrophils is not increased in localized Wegener's granulomatosis (WG) and Churg-Strauss syndrome (CSS). Clin Exp Rheumatol (2010) 0.78
Biological therapies: new treatment options for ANCA-associated vasculitis? Expert Opin Biol Ther (2007) 0.78
Complex genetics of Wegener granulomatosis. Autoimmun Rev (2005) 0.78
Active disease and residual damage in treated Wegener's granulomatosis: an observational study using pulmonary high-resolution computed tomography. Eur Radiol (2002) 0.77
Acute inflammatory syndrome with elevated procalcitonin induced by mycophenolate sodium. J Rheumatol (2012) 0.77
T cell alterations and lymphoid neogenesis favoring autoimmunity in Wegener's granulomatosis. Arthritis Rheum (2007) 0.77
Anticitrullinated protein/peptide antibodies in rheumatoid arthritis. Dtsch Arztebl Int (2009) 0.77
A case of destructive Wegener's granulomatosis complicated by cytomegalovirus infection. Nat Clin Pract Rheumatol (2006) 0.77
Expansion of CD28-CD27-NKG2D+ effector memory T cells and predominant Th1-type response during febrile attacks in tumor necrosis factor-associated periodic syndrome. Isr Med Assoc J (2006) 0.76
Selective killing of B-cell hybridomas targeting proteinase 3, Wegener's autoantigen. Immunology (2004) 0.76
CD28- T cells display features of effector memory T cells in Wegener's granulomatosis. Kidney Int (2004) 0.76